CORRECTION
Free Access
Correction
First published: 14 April 2020
In an article1 titled “Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function” by Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Yukari Tsubata, Takamasa Hotta, Kenji Tamura, Noboru Yamamoto, Hironobu Minami, "50 mg" in the cell of cohort 3 and BSA 1.25 ≤ 1.5 (m2) should be "40 mg" in Table 1.
|
Cohort eGFR (mL/min/1.73m2) |
|||||
|---|---|---|---|---|---|
|
Cohort 1 ≥80 |
Cohort 2 50-79 |
Cohort 3 30-49 |
Cohort 4 <30 |
||
| BSA (m2) | ≤1.25 |
40 mg bid N = 0 |
40 mg bid N = 0 |
40 mg bid N = 0 |
25 mg bid N = 1 |
| 1.25 ≤ 1.5 |
50 mg bid N = 6 |
50 mg bid N = 2 |
40 mg bid N = 2 |
40 mg bid N = 0 |
|
| >1.5 |
60 mg bid N = 4 |
60 mg bid N = 8 |
50 mg bid N = 8 |
40 mg bid N = 2 |
|
Note
- The number in each column indicates the actual number of patients enrolled in each cohort.
- Abbreviations: BSA, body surface area; eGFR, estimated glomerular filtration rate.
The authors apologize for the errors.
